IS7328A - Útskiptar kínasólínafleiður sem hemlar gegn árórakínösum - Google Patents

Útskiptar kínasólínafleiður sem hemlar gegn árórakínösum

Info

Publication number
IS7328A
IS7328A IS7328A IS7328A IS7328A IS 7328 A IS7328 A IS 7328A IS 7328 A IS7328 A IS 7328A IS 7328 A IS7328 A IS 7328A IS 7328 A IS7328 A IS 7328A
Authority
IS
Iceland
Prior art keywords
aerokinases
inhibit
replaced
quinazoline derivatives
quinazoline
Prior art date
Application number
IS7328A
Other languages
English (en)
Other versions
IS2758B (is
Inventor
Henri Jung Frederic
Rene Pasquet Georges
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS7328A publication Critical patent/IS7328A/is
Publication of IS2758B publication Critical patent/IS2758B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS7328A 2001-12-24 2004-06-21 Setnar kínasólínafleiður sem hemlar gegn Áróra kínösum IS2758B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01403357 2001-12-24
PCT/GB2002/005845 WO2003055491A1 (en) 2001-12-24 2002-12-20 Substituted quinazoline derivatives as inhibitors of aurora kinases

Publications (2)

Publication Number Publication Date
IS7328A true IS7328A (is) 2004-06-21
IS2758B IS2758B (is) 2011-10-15

Family

ID=8183051

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7328A IS2758B (is) 2001-12-24 2004-06-21 Setnar kínasólínafleiður sem hemlar gegn Áróra kínösum

Country Status (32)

Country Link
US (2) US7402585B2 (is)
EP (1) EP1463506B1 (is)
JP (1) JP4498741B2 (is)
KR (1) KR101029281B1 (is)
CN (1) CN100491372C (is)
AR (1) AR038052A1 (is)
AT (1) ATE446093T1 (is)
AU (1) AU2002353196B2 (is)
BR (1) BRPI0215312B8 (is)
CA (1) CA2471577C (is)
CY (1) CY1109681T1 (is)
DE (1) DE60234125D1 (is)
DK (1) DK1463506T3 (is)
ES (1) ES2333702T3 (is)
HK (1) HK1076598A1 (is)
HU (1) HU229477B1 (is)
IL (1) IL162541A0 (is)
IS (1) IS2758B (is)
MX (1) MXPA04006260A (is)
MY (1) MY141739A (is)
NO (1) NO328159B1 (is)
NZ (1) NZ533440A (is)
PL (1) PL211694B1 (is)
PT (1) PT1463506E (is)
RU (1) RU2323215C2 (is)
SA (1) SA03230531B1 (is)
SI (1) SI1463506T1 (is)
TW (1) TWI335818B (is)
UA (1) UA82058C2 (is)
UY (1) UY27604A1 (is)
WO (1) WO2003055491A1 (is)
ZA (1) ZA200404923B (is)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036587A2 (en) 2000-11-01 2002-05-10 Cor Therapeutics, Inc. Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides
RU2323215C2 (ru) * 2001-12-24 2008-04-27 Астразенека Аб Замещенные производные хиназолина как ингибиторы ауроракиназы
ES2400339T3 (es) 2002-07-15 2013-04-09 Symphony Evolution, Inc. Compuestos, composiciones farmacéuticas de los mismos y su uso en el tratamiento del cáncer
DK1847539T3 (da) 2002-12-24 2009-11-09 Astrazeneca Ab Quinazolin-derivater
CA2522079A1 (en) * 2003-04-16 2004-11-04 Astrazeneca Ab Quinazoline derivatives for treatment of cancer
ES2308182T3 (es) * 2003-06-02 2008-12-01 Astrazeneca Ab Derivadosde (3-((quinazolin-4-il)amino)-1h-pirazol-1-il)acetamida y compuestos relacionados como inhibidores de quinasas aurora para el tratamiento de enfermedades proliferativas tales como el cancer.
TW200505452A (en) * 2003-06-17 2005-02-16 Astrazeneca Ab Chemical compounds
CA2531142A1 (en) * 2003-07-03 2005-01-13 Cambridge University Technical Services Ltd Use of aurora kinase inhibitors for reducing the resistance of cancer cells
US7452895B2 (en) * 2003-08-14 2008-11-18 Array Biopharma Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
EP2612853A1 (en) 2003-09-26 2013-07-10 Exelixis Inc. c-Met modulators and methods of use
US20090099165A1 (en) 2003-10-14 2009-04-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
US7326712B2 (en) * 2003-10-14 2008-02-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Substituted tricyclic compounds as protein kinase inhibitors
EP1694686A1 (en) * 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
EP1763524A1 (en) * 2004-04-23 2007-03-21 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
UA85706C2 (en) 2004-05-06 2009-02-25 Уорнер-Ламберт Компани Ллси 4-phenylaminoquinazolin-6-yl amides
ATE485300T1 (de) * 2004-07-16 2010-11-15 Sunesis Pharmaceuticals Inc Als aurora-kinase-inhibitoren nutzbare thienopyrimidine
US7550598B2 (en) * 2004-08-18 2009-06-23 Takeda Pharmaceutical Company Limited Kinase inhibitors
AR050948A1 (es) * 2004-09-24 2006-12-06 Hoffmann La Roche Derivados de ftalazinona; su obtencion y su utilizacion en la fabricacion de medicamentos para el tratamiento del cancer.
AU2005293336B2 (en) 2004-10-12 2009-05-28 Astrazeneca Ab Quinazoline derivatives
US7713973B2 (en) * 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
CA2587427A1 (en) 2004-11-17 2006-05-26 Miikana Therapeutics, Inc. Kinase inhibitors
GB0427917D0 (en) * 2004-12-21 2005-01-26 Astrazeneca Ab Chemical compounds
CA2607727A1 (en) 2005-04-28 2006-11-09 Mitsubishi Tanabe Pharma Corporation Cyanopyridine derivative and use thereof as medicine
GB0510963D0 (en) * 2005-05-28 2005-07-06 Astrazeneca Ab Chemical compounds
US7932257B2 (en) 2005-07-22 2011-04-26 Sunesis Pharmaceuticals, Inc. Substituted pyrazolo[4,3-d]pyrimidines as aurora kinase inhibitors
ES2535854T3 (es) * 2005-09-30 2015-05-18 Miikana Therapeutics, Inc. Compuestos de pirazol sustituidos
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
GB0601215D0 (en) * 2006-01-21 2006-03-01 Astrazeneca Ab Chemical compounds
US7560551B2 (en) 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
KR101332975B1 (ko) 2006-01-23 2013-11-25 암젠 인크 오로라 키나제 조절제 및 사용 방법
US7868177B2 (en) 2006-02-24 2011-01-11 Amgen Inc. Multi-cyclic compounds and method of use
UY30183A1 (es) * 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
JP2009528336A (ja) * 2006-03-02 2009-08-06 アストラゼネカ アクチボラグ キノリン誘導体
CN101405001A (zh) * 2006-03-20 2009-04-08 霍夫曼-拉罗奇有限公司 抑制btk和syk蛋白质激酶的方法
US20090221599A1 (en) * 2006-03-20 2009-09-03 Edward Boyd Phthalazinone pyrazole derivatives, their manufacture and use as pharmaceutical agents
GB0609617D0 (en) 2006-05-16 2006-06-21 Astrazeneca Ab Process & intermediate
GB0609621D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Novel co-crystal
WO2007136592A2 (en) * 2006-05-18 2007-11-29 Amphora Discovery Corporation 2-0x0-l,2-dihydr0quin0line derivatives, compositions, and uses thereof as antiproliferative agents
GB0619342D0 (en) * 2006-09-30 2006-11-08 Vernalis R&D Ltd New chemical compounds
EP2128272A4 (en) 2006-10-05 2010-06-16 Banyu Pharma Co Ltd GENE / PROTEIN MARKERS FOR PREDICTING OR DIAGNOSING THE PHARMACOLOGICAL EFFECTIVENESS OF AN AORORA A INHIBITOR
SG175609A1 (en) 2006-10-09 2011-11-28 Takeda Pharmaceutical Kinase inhibitors
EP2223925A1 (en) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
US7776857B2 (en) 2007-04-05 2010-08-17 Amgen Inc. Aurora kinase modulators and method of use
US20090029992A1 (en) * 2007-06-11 2009-01-29 Agoston Gregory E Substituted pyrazole compounds
JP2010532381A (ja) 2007-06-29 2010-10-07 サネシス ファーマシューティカルズ， インコーポレイテッド Ｒａｆキナーゼ阻害剤として有用な複素環式化合物
EP2262796A1 (en) 2008-03-04 2010-12-22 Vitae Pharmaceuticals, Inc. Aurora kinase inhibitors
WO2009117157A1 (en) 2008-03-20 2009-09-24 Amgen Inc. Aurora kinase modulators and method of use
US9126935B2 (en) 2008-08-14 2015-09-08 Amgen Inc. Aurora kinase modulators and methods of use
TWI447108B (zh) 2009-01-16 2014-08-01 Exelixis Inc Ｎ－（４－｛〔６，７雙（甲氧基）喹啉－４－基〕氧基｝苯基）－ｎ’－（４－氟苯基）環丙烷－１，１－二甲醯胺之蘋果酸鹽及其結晶型
BRPI1008325A2 (pt) * 2009-02-11 2020-08-25 Merck Patent Gmbh carboxamidas azaeterocíclicas de amino
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
EP2465842A1 (de) * 2010-12-17 2012-06-20 Sika Technology AG Amine mit sekundären aliphatischen Aminogruppen
EA023998B1 (ru) 2011-03-04 2016-08-31 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Аминохинолины в качестве ингибиторов киназ
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
RU2014141674A (ru) 2012-03-16 2016-05-10 Аксикин Фармасьютикалз, Инк. 3,5-диаминопиразоловые ингибиторы киназы
CN104024246B (zh) * 2012-03-27 2016-03-02 广东东阳光药业有限公司 作为欧若拉激酶抑制剂的取代嘧啶衍生物
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
TW201425307A (zh) 2012-09-13 2014-07-01 Glaxosmithkline Llc 作為激酶抑制劑之胺基－喹啉類
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
JP6301374B2 (ja) * 2013-02-21 2018-03-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ キナーゼ阻害剤としてのキナゾリン類
CN104098551B (zh) * 2013-04-03 2019-03-22 广东东阳光药业有限公司 作为欧若拉激酶抑制剂的取代喹唑啉类衍生物
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
AP2016009088A0 (en) 2013-09-16 2016-03-31 Astrazeneca Ab Therapeutic polymeric nanoparticles and methods of making and using same
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
WO2015077375A1 (en) 2013-11-20 2015-05-28 Signalchem Lifesciences Corp. Quinazoline derivatives as tam family kinase inhibitors
RU2715893C2 (ru) 2014-03-26 2020-03-04 Астекс Терапьютикс Лтд Комбинации ингибитора fgfr и ингибитора igf1r
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
PL3122358T3 (pl) 2014-03-26 2021-06-14 Astex Therapeutics Ltd. Połączenia inhibitorów fgfr i cmet w leczeniu nowotworu
KR102034202B1 (ko) 2014-12-23 2019-10-18 에스엠에이 세라퓨틱스 아이엔씨. 3,5-디아미노피라졸 키나제 억제제
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
BR112018005637B1 (pt) 2015-09-23 2023-11-28 Janssen Pharmaceutica Nv Compostos derivados de quinoxalina, quinolina e quinazolinona,composições farmacêuticas que os compreende, e uso dos referidos compostos
HUE057090T2 (hu) 2015-09-23 2022-04-28 Janssen Pharmaceutica Nv BI-heteroaril-szubsztituált 1,4-benzodiazepinek és alkalmazásuk rák kezelésében
CN112939948B (zh) * 2019-12-11 2022-05-17 苏州美诺医药科技有限公司 新型含喹唑啉类化合物及其中间体与应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
WO1992020642A1 (en) 1991-05-10 1992-11-26 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (is) 1994-11-12 1997-12-01 Zeneca Ltd
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
CN1161352C (zh) * 1998-10-08 2004-08-11 阿斯特拉曾尼卡有限公司 喹唑啉衍生物
WO2001021596A1 (en) 1999-09-21 2001-03-29 Astrazeneca Ab Quinazoline derivatives and their use as pharmaceuticals
GB9922171D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
GB0006864D0 (en) * 2000-03-21 2000-05-10 Smithkline Beecham Plc New use
US6919338B2 (en) * 2000-06-28 2005-07-19 Astrazeneca Ab Substituted quinazoline derivatives and their use as inhibitors of aurora-2 kinase
US6610677B2 (en) * 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
GB0124299D0 (en) * 2001-10-10 2001-11-28 Astrazeneca Ab Crystal structure of enzyme and uses thereof
RU2323215C2 (ru) * 2001-12-24 2008-04-27 Астразенека Аб Замещенные производные хиназолина как ингибиторы ауроракиназы
US7105425B1 (en) * 2002-05-16 2006-09-12 Advanced Micro Devices, Inc. Single electron devices formed by laser thermal annealing
DK1847539T3 (da) * 2002-12-24 2009-11-09 Astrazeneca Ab Quinazolin-derivater
CA2522079A1 (en) * 2003-04-16 2004-11-04 Astrazeneca Ab Quinazoline derivatives for treatment of cancer
ES2308182T3 (es) * 2003-06-02 2008-12-01 Astrazeneca Ab Derivadosde (3-((quinazolin-4-il)amino)-1h-pirazol-1-il)acetamida y compuestos relacionados como inhibidores de quinasas aurora para el tratamiento de enfermedades proliferativas tales como el cancer.
US20090036474A1 (en) * 2004-10-12 2009-02-05 Patrick Ple Quinazoline derivatives for use against cancer
GB0427917D0 (en) * 2004-12-21 2005-01-26 Astrazeneca Ab Chemical compounds
WO2006129064A1 (en) * 2005-05-28 2006-12-07 Astrazeneca Ab Quinazolines and their use as aurora kinase inhibitors
GB0601215D0 (en) * 2006-01-21 2006-03-01 Astrazeneca Ab Chemical compounds
GB0609617D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Process & intermediate
GB0609619D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Combination
GB0609621D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Novel co-crystal
CN101896227A (zh) * 2007-12-12 2010-11-24 阿斯利康(瑞典)有限公司 包含mek抑制剂和极光激酶抑制剂的组合

Also Published As

Publication number Publication date
CN100491372C (zh) 2009-05-27
TWI335818B (en) 2011-01-11
HUP0402454A3 (en) 2009-08-28
HK1076598A1 (en) 2006-01-20
JP4498741B2 (ja) 2010-07-07
RU2004122926A (ru) 2005-07-10
SA03230531A (ar) 2005-12-03
SI1463506T1 (sl) 2010-01-29
AU2002353196A1 (en) 2003-07-15
WO2003055491A1 (en) 2003-07-10
DE60234125D1 (de) 2009-12-03
KR20040066929A (ko) 2004-07-27
KR101029281B1 (ko) 2011-04-18
DK1463506T3 (da) 2010-01-11
PL371253A1 (en) 2005-06-13
RU2323215C2 (ru) 2008-04-27
IS2758B (is) 2011-10-15
ZA200404923B (en) 2005-11-30
US20050070561A1 (en) 2005-03-31
NZ533440A (en) 2006-08-31
PL211694B1 (pl) 2012-06-29
UY27604A1 (es) 2003-07-31
TW200410697A (en) 2004-07-01
IL162541A0 (en) 2005-11-20
PT1463506E (pt) 2009-12-10
JP2005525307A (ja) 2005-08-25
ES2333702T3 (es) 2010-02-26
BRPI0215312B8 (pt) 2021-05-25
SA03230531B1 (ar) 2008-09-08
CN1620296A (zh) 2005-05-25
CY1109681T1 (el) 2014-08-13
NO328159B1 (no) 2009-12-21
CA2471577C (en) 2011-08-02
AU2002353196B2 (en) 2008-01-17
UA82058C2 (uk) 2008-03-11
HU229477B1 (en) 2014-01-28
US7402585B2 (en) 2008-07-22
EP1463506B1 (en) 2009-10-21
AR038052A1 (es) 2004-12-22
EP1463506A1 (en) 2004-10-06
NO20043158L (no) 2004-09-16
MY141739A (en) 2010-06-15
CA2471577A1 (en) 2003-07-10
BRPI0215312B1 (pt) 2018-03-27
ATE446093T1 (de) 2009-11-15
HUP0402454A2 (hu) 2005-03-29
MXPA04006260A (es) 2005-03-31
BR0215312A (pt) 2004-12-07
US20090215770A1 (en) 2009-08-27

Similar Documents

Publication Publication Date Title
IS7328A (is) Útskiptar kínasólínafleiður sem hemlar gegn árórakínösum
IS7240A (is) Kínasólínafleiður sem æxliseyðandi efni
IS7241A (is) Kínasólínafleiður sem æxliseyðandi efni
IS6886A (is) Kínasólín sem MMP-13 hindrar
IS7362A (is) Kínasólín efnasambönd
DE60328735D1 (de) Chinazolinderivate
IS7884A (is) Díasepínóindól afleiður sem kínasa hindrar
DE60227853D1 (de) Substituierte Pyridinylamine
IS6298A (is) Teridínón sem tálmar kínasa
IS6971A (is) Ný efnasambönd
ATE319451T1 (de) Tetrahydrochinolin-derivate
ATE312827T1 (de) 3-substituierte-4-pyrimidonderivate
DE50206892D1 (de) Substituierte imidazotriazinone
DK1373228T3 (da) Substituerede fluoralkoxyphenylsulfonylurinstoffer
NO20035573L (no) Kinazolinderivater
DE60239393D1 (de) Verriegelungsanordnung
DE60231830D1 (de) Verriegelungsanordnung
DE50202174D1 (de) Schliesszylinder
DE60223031D1 (de) Arylpiperazin gebundene tetrahydroindolonderivate
DK1406858T3 (da) Substituerede 4-aminocyklohexanoler
DE60203764D1 (de) Flachprofil-Wegwerfpolymerkapillarkissen
DE60202381D1 (de) Paroxetin-n-formyl-derivate
DE60216967D1 (de) Substituierte cyclohexanderivate
FI4977U1 (fi) Lukituslaite
SE0100694D0 (sv) DHFR inhibitors